Almotriptan (154323-57-6)

  Almotriptan (154323-57-6), which also can be called for Almogran ; 1-[[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl]sulfonyl]pyrrolidine ; N,N-Dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]-ethanamine , it is a triptan drug discovered by Almirall Prodesfarma and licensed to Ortho-McNeil for the treatment of migraine headaches. It is available in strengths of 6.25 and 12.5 mg as a tablet and is indicated for the acute treatment of migraine with or without aura in adults.

 In the United States and Canada Almotriptan is available under the name Axert only by prescription. Axert for oral administration contains almotriptan malate equivalent to 6.25 or 12.5 mg of almotriptan. Each compressed tablet contains the following inactive ingredients: cellulose, mannitol, povidone, sodium stearyl fumarate, sodium starch glycolate, titanium dioxide, polyethylene glycol, hypromellose, propylene glycol, iron oxide (6.25 mg only), FD & C Blue No. 2 (12.5 mg only), and carnauba wax. The brand Almogran is used in Belgium, France, Finland, Italy, Portugal, the United Kingdom and Spain. Each 12.5 mg. tablet contains the following inactive ingredients: carnauba wax, indigo carmine (E132), hypromellose, macrogol 400, microcrystalline cellulose, mannitol, povidone, sodium starch glycollate, propylene glycol, titanium dioxide (E171) and sodium stearyl fumarate.